The relationship of vitamin D-binding protein with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
https://doi.org/10.31146/1682-8658-ecg-240-8-13-19
Abstract
Aim of the investigation. To study the relationship of blood levels of vitamin D-binding protein (VDBP) with clinical and laboratory manifestations of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Materials and methods. The study included 80 patients with type 2 diabetes mellitus aged 33 to 69 years (67 women, 13 men). NAFLD was detected in 75.0% patients with type 2 diabetes mellitus. Severe liver steatosis was observed in 40.0% cases of NAFLD, fibrosis F3-4 in 23.3%. Serum levels of VDBP were determined by enzyme-linked immunosorbent assay. Results. The presence of NAFLD in patients with type 2 diabetes mellitus was characterized by lower blood levels of VDBP. Biochemical syndromes of liver pathology, as well as manifestations of diabetes mellitus (except for its duration) did not affect serum levels of VDBP in NAFLD. In patients with NAFLD and obesity, abdominal obesity or dyslipidemia, a lower concentration of VDBP in blood was determined. VDBP values did not depend on the presence of arterial hypertension and metabolic syndrome in NAFLD. Patients with severe liver steatosis or fibrosis F3-4 had lower blood levels of VDBP. Conclusion. Thus, in NAFLD associated with type 2 diabetes mellitus, there is a decrease of blood levels of VDBP, which is associated with the duration of diabetes, the presence of obesity, abdominal obesity and dyslipidemia. Cases of NAFLD with severe steatosis or severe fibrosis/liver cirrhosis are characterized by a lower serum concentration of VDBP.
About the Authors
A. V. Yagoda
Stavropol State Medical University
Russian Federation
Russian Federation
E. O. Demurcheva
Regional Endocrinological Dispensary
Russian Federation
Russian Federation
P. V. Koroy
Stavropol State Medical University
Russian Federation
Russian Federation
T. R. Dudov
Stavropol State Medical University
Russian Federation
Russian Federation
References
1. Pop T. L., Sîrbe C., Benta G. et al. The Role of vitamin D and vitamin D binding protein in chronic liver diseases.Int. J. Mol. Sci. 2022; 23: 10705. doi: 10.3390/ijms231810705.
2. Ravaioli F., Pivetti A., Di Marco L. et al. Role of vitamin D in liver disease and complications of advanced chronic liver disease.Int. J. Mol. Sci. 2022; 23: 9016. doi: 10.3390/ijms23169016.
3. Bouillon R., Schuit F., Antonio L. et al. Vitamin D binding protein: a historic overview. Front. Endocrinol. 2020; 10: 910. doi: 10.3389/fendo.2019.00910.
4. Bikle D. D., Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. Front. Endocrinol. 2019; 10: 317. doi: 10.3390/ ijms24054642.
5. Viloria K., Nasteska D., Ast J. et al. GC-Globulin/vitamin D-binding protein is required for pancreatic α-cell adaptation to metabolic stress. Diabetes. 2023; 72: 275-289. doi: 10.2337/db22-0326.
6. Grama A., Burac L., Aldea C. O. et al. Vitamin D-binding protein (Gc-Globulin) in acute liver failure in children. Diagnostics. 2020; 10: 278. doi: 10.3390/diagnostics10050278.
7. Huang C. Z., Zhang J., Zhang L. et al. Serum vitamin D and vitamin-D-binding protein levels in children with chronic hepatitis B. World J. Gastroenterol. 2021; 27 (3): 255-266. doi: 10.3748/wjg.v27.i3.255.
8. El-masry A. S., Medhat A. M., El-Bendary M. et al. Vitamin D receptor rs3782905 and vitamin D binding protein rs7041 polymorphisms are associated with hepatocellular carcinoma susceptibility in cirrhotic HCV patients. BMC Med. Genomics. 2023; 16: 319. doi: 10.1186/s12920-023-01749-8.
9. Xie C. N., Yue M., Huang P. et al. Vitamin D binding protein polymorphisms influence susceptibility to hepatitis C virus infection in a high-risk Chinese population. Gene. 2018; 679: 405-411. doi: 10.1016/j.gene.2018.09.021.
10. Lee S., Jin M. H., Yoon J.-H. The contribution of vitamin D insufficiency to the onset of steatotic liver disease among individuals with metabolic dysfunction. Sci. Rep. 2024; 14: 6714. doi: 10.1038/s41598-024-57380-9.
11. Yagoda A. V., Koroy P. V., Demurcheva E. O. et al. Vitamin D as a marker of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medical News of North Caucasus. 2023; 18 (2): 131-135. doi: 10.14300/mnnc.2023.18028.
12. Zhao X., Sun J., Xin S. et al. Correlation between serum 25 (OH) D levels with insulin resistance and metabolic associated fatty liver disease - a retrospective study based on chinese patients with newly diagnosed type 2 diabetes mellitus. Curr. Diabetes Rev. 2025; 21 (7): 56-66. doi: 10.2174/0115733998297640240611065605.
13. Wang M., Wang M., Zhang R. et al. Influences of vitamin D levels and vitamin D-binding protein polymorphisms on nonalcoholic fatty liver disease risk in a Chinese population. Ann. Nutr. Metab. 2022; 78: 61-72. doi: 10.1159/000522193.
14. Rinella M. E., Neuschwander-Tetri B. A., Siddiqui M. S. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77 (5): 1797-1835. doi: 10.1097/HEP.0000000000000323.
15. Sahu P., Chhabra P., Mehendale A. M. A comprehensive review on non-alcoholic fatty liver disease. Cureus. 2023; 15: e50159. doi: 10.7759/cureus.50159.
16. Drapkina O. M., Evstifeeva S. E., Shalnova S. A. et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies). Cardiovascular Therapy and Prevention. 2025; 24 (2): 4316. (In Russ.) doi: 10.15829/1728-8800-2025-4316.@@ Драпкина О. М., Евстифеева С. Е., Шальнова С. А. и др. Распространенность неалкогольной жировой болезни печени и ее ассоциации с сердечно-сосудистыми факторами риска (данные российских эпидемиологических исследований). Кардиоваскулярная терапия и профилактика. 2025; 24 (2): 4316. doi: 10.15829/1728-8800-2025-4316.
17. Mantovani A., Taverna A., Cappelli D. et al. Long-term adverse effect of liver stiffness on glycaemic control in type 2 diabetic patients with nonalcoholic fatty liver disease: a pilot study.Int. J. Mol. Sci. 2022; 23: 12481. doi: 10.3390/ijms232012481.
18. Younossi Z. M., Golabi P., de Avila L. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 2019; 71 (4): 793-801. doi: 10.1016/j.jhep.2019.06.021.
19. Choe Y., Lee Y. J., Kim J. H. et al. Free, bioavailable 25-hydroxyvitamin D levels and their association with diabetic ketoacidosis in children with type 1 diabetes at diagnosis. Front. Endocrinol. 2022; 13: 997631. doi: 10.3389/fendo.2022.997631.
20. Cave E. M., Bhola S., Crowther N. J. et al. The association of vitamin D binding protein levels and genotypes with type 1 diabetes in the black South African population. BMC Endocr. Disord. 2022; 22 (1): 182. doi: 10.1186/s12902-022-01097-1.
21. Kim H. Y., Lee Y. A., Jung H. W. et al. A lack of association between vitamin D-binding protein and 25-hydroxyvitamin D concentrations in pediatric type 1 diabetes without microalbuminuria. Ann. Pediatr. Endocrinol. Metab. 2017; 22 (4): 247-252. doi: 10.6065/apem.2017.22.4.247.
22. Zhao X., Li B., Li X. et al. Association of serum 25-hydroxyvitamin D levels, vitamin D-binding protein levels, and diabetes mellitus: two-sample Mendelian randomization. Medicine (Baltimore). 2024; 103 (20): e38219. doi: 10.1097/MD.0000000000038219.
23. Gotlieb N., Tachlytski I., Lapidot Y. et al. Hepatitis B virus downregulates vitamin D receptor levels in hepatoma cell lines, thereby preventing vitamin D-dependent inhibition of viral transcription and production. Mol. Med. 2018; 24: 53. doi: 10.1186/s10020-018-0055-0.
24. Hu Y. C., Wang W. W., Jiang W. Y. et al. Low vitamin D levels are associated with high viral loads in patients with chronic hepatitis B: a systematic review and meta-analysis. BMC Gastroenterol. 2019; 19: 84. doi: 10.1186/s12876-019-1004-2.
25. Abdella N. A., Mojiminiyi O. A. Vitamin D-binding protein clearance ratio is significantly associated with glycemic status and diabetes complications in a predominantly vitamin D-deficient population. J. Diabetes Res. 2018; 2018: 6239158. doi: 10.1155/2018/6239158.
26. Thanapirom K., Suksawatamnuay S., Sukeepaisarnjaroen W. et al. Vitamin D-binding protein gene polymorphism predicts pegylated interferon-related HBsAg seroclearance in HBeAg-negative thai chronic hepatitis B patients: a multicentre study. Asian Pac. J. Cancer Prev. 2019; 20: 1257-1264. doi: 10.31557/APJCP.2019.20.4.1257.
27. Karuwanarint P., Phonrat B., Tungtrongchitr A. et al. Vitamin D-binding protein and its polymorphisms as a predictor for metabolic syndrome. Biomark. Med. 2018; 12 (5): 465-473. doi: 10.2217/bmm-2018-0029.
28. Pelczyńska M., Grzelak T., Sperling M. et al. Impact of 25-hydroxyvitamin D, free and bioavailable fractions of vitamin D, and vitamin D binding protein levels on metabolic syndrome components. Arch. Med. Sci. 2017; 13 (4): 745. doi: 10.5114/aoms.2016.58594.
29. Setayesh L., Casazza K., Moradi N. et al. Association of vitamin D-binding protein and vitamin D3 with insulin and homeostatic model assessment (HOMA-IR) in overweight and obese females. BMC Res. Notes. 2021; 14 (1): 193. doi: 10.1186/s13104-021-05608-6.
30. Kuliczkowska-Plaksej J., Pasquali R., Milewicz A. et al. Serum vitamin D binding protein level associated with metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. Horm. Metab. Res. 2019; 51 (1): 54-61. doi: 10.1055/a-0759-7533.
31. Fawzy M. S., Abu AlSel B. T. Assessment of vitamin D-binding protein and early prediction of nephropathy in type 2 Saudi diabetic patients. J. Diabetes Res. 2018; 2018: 8517929. doi: 10.1155/2018/8517929.
32. Hidalgo-Bravo A., Rivera-Paredez B., León-Reyes G. et al. Unravelling the contribution of the rs7041 and rs4588 polymorphisms of the GC gene and serum VDBP levels for developing metabolic syndrome in the Mexican population.Int. J. Mol. Sci. 2022; 23 (18): 10581. doi: 10.3390/ijms231810581.
33. Delanghe J. R., Clement F., Speeckaert M. M. et al. Vitamin D binding protein polymorphism is associated with body weight in females. Horm. Mol. Biol. Clin. Investig. 2025; 46 (3): 133-138. doi: 10.1515/hmbci-2025-0028.
34. Xiao K., Zhang D.-C., Hu Y. et al. Potential roles of vitamin D binding protein in attenuating liver injury in sepsis. Mil. Med. Res. 2022; 9: 4. doi: 10.1186/s40779-022-00365-4.
Review
For citations:
Yagoda A.V., Demurcheva E.O., Koroy P.V., Dudov T.R. The relationship of vitamin D-binding protein with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Experimental and Clinical Gastroenterology. 2025;(8):13-19. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-240-8-13-19
Views:
7
JATS XML
Email this article 
